Lexicon Pharmaceuticals NASDAQ: LXRX expects first-quarter results next year from a late-stage study of sotagliflozin in hypertrophic cardiomyopathy, while preparing to resubmit the drug for type 1 diabetes in the first quarter of 2027, company executives said at a Jefferies healthcare conference.
Chief Executive Officer Mike Exton said the company has focused its pipeline on serious cardiometabolic diseases over the past two years. Alongside sotagliflozin, Lexicon has a phase 3-ready program for diabetic peripheral neuropathy and a partnership with Novo Nordisk on LX9851 for obesity and other indications, he said.
Heart Disease Trial Approaches Readout
The fully enrolled phase 3 SONATA study is testing sotagliflozin in patients with both obstructive and non-obstructive hypertrophic cardiomyopathy, or HCM. Chief Medical Officer Craig Granowitz said the trial enrolled 542 patients: 440 with non-obstructive disease and 102 with obstructive disease.
Exton said Lexicon expects to report the primary endpoint—the change in KCCQ score across the combined patient population—and some safety details in the initial release. Most secondary endpoint results would likely be reserved for a medical meeting, he said.
Granowitz said the study was powered around a roughly five-point placebo-adjusted difference in KCCQ score at 24 weeks. He said the company expects a similar effect across the two HCM subgroups, although the results are not yet available.
The company’s executives argued that sotagliflozin could address an unmet need in non-obstructive HCM and potentially be used alone or alongside cardiac myosin inhibitors. Granowitz said about 40 trial participants were taking a myosin inhibitor. Exton cautioned that the study was not powered to demonstrate differences or effects in that subgroup.
Granowitz also said the trial used relatively broad entry criteria, including allowing patients with an ejection fraction as low as 50% and patients taking underlying medications. He said both HCM subgroups had similar baseline KCCQ scores in the upper 50s, indicating a symptomatic population.
If the HCM study is successful and the drug receives approval, Exton said Lexicon intends to market it itself. He also said the company plans a separate pricing approach for HCM, with a new drug name and product code, as it has pursued for type 1 diabetes. Sotagliflozin is already approved for heart failure.
Diabetes Resubmission and Safety Data
Lexicon plans to resubmit sotagliflozin, under the name ZYNQUISTA, for type 1 diabetes in the first quarter of 2027. Exton said a potential approval could come in 2027.
Exton said the Food and Drug Administration had concerns about rates of diabetic ketoacidosis, or DKA, and wanted new prospective safety data. Lexicon is using data from a third-party, open-label study called STENO1 to support the resubmission.
Granowitz said the company had aligned with the FDA on criteria including at least 200 patient-years of exposure and a DKA rate below the approximately 3.5 cases per 100 patient-years seen in the earlier inTandem program. As of the end of August, he said, STENO1 had reached the exposure threshold and recorded a DKA rate of roughly one case per 100 patient-years, similar to the study’s untreated control group.
Granowitz said STENO1 continues to enroll and that Lexicon expects to update the FDA with additional data during the review and afterward. Exton said the company believes it has fulfilled the criteria set out by the agency.
On intellectual property, Exton said sotagliflozin has composition-of-matter protection and patent term extension through 2033, with secondary patents extending into the 2040s.
About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals is a biopharmaceutical company based in The Woodlands, Texas. Founded in 1995 as Lexicon Genetics, the company uses drug discovery and development research to create medicines for serious diseases, with a focus on areas of unmet medical need. Its commercial product, Inpefa (sotagliflozin), is approved in the United States to reduce the risk of cardiovascular death and worsening heart failure in adults with heart failure. Lexicon also develops investigational medicines, including candidates studied for neuropathic pain and other conditions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lexicon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexicon Pharmaceuticals wasn't on the list.
While Lexicon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.